Trial Profile
Dose Climbing Trial of Anlotinib Plus Pemetrexed/Docetaxel in the Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel (Primary) ; Pemetrexed (Primary) ; Cobalamin; Dexamethasone; Folic acid
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 02 Jul 2018 New trial record